Lupin launches Luforbec 100/6 for adult asthma and COPD treatment in Germany
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
The company has received Export Performance Award - API & Intermediaries Gold Star for the year 2021-22
This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments
OVAPEX is a unique formula developed by the team of scientists and doctors at Green Milk Concepts
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.
The investment is part of Croda’s continuing commitment to develop high performance pharmaceutical ingredients and technologies for life sciences.
Subscribe To Our Newsletter & Stay Updated